mRNA is known to the public due to the COVID-19 pandemic. The mRNA vaccine made from it has the characteristics of fast response to pathogen variation, simple production process, and large-scale expansion. With the increasing demand for mRNA vaccines, the industry has also begun to realize the feasibility and advantages of mRNA vaccines/drugs, followed by an increasing number of clinical applications for mRNA vaccines.
ProBio provides one-stop solution from plasmid and linearized DNA manufacturing, IVT-mRNA preparation, LNP encapsulation, sterile filtration and IND filing. Combined with the experience of multiple previous projects, it helps customers' projects to accelerate into the clinical trial stage.
mRNA-LNP Service Overview
mRNA small-scale test
Process development for DS/DP
Verification run
Pilot scale production
Engineering run
Analytical development for DS/DP
QC test and release
Stability study
IND documentation
Platform Advantages
- One-stop solution: Plasmid + Linearized DNA + IVT-mRNA + mRNA-LNP
- Shorten project cycle: from Plasmid to mRNA
- IVT-mRNA：enzymatic capping and co-transcriptional capping（License in）
- mRNA-LNP: microfluidic encapsulation, encapsulation efficiency up to 99.7%
- mRNA QC：comprehensive & in-house, compliant with the requirement in US/EU/CN
- >10 mRNA IND approvals (NMPA, FDA, PMDA, MFDS, Ministry of Health)
- >50 global mRNA projects
